TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of $6.51 billion. The enterprise value is $6.88 billion.
| Market Cap | 6.51B |
| Enterprise Value | 6.88B |
Important Dates
The next confirmed earnings date is Monday, August 3, 2026, before market open.
| Earnings Date | Aug 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TG Therapeutics has 141.72 million shares outstanding. The number of shares has decreased by -5.56% in one year.
| Current Share Class | 141.72M |
| Shares Outstanding | 141.72M |
| Shares Change (YoY) | -5.56% |
| Shares Change (QoQ) | -1.74% |
| Owned by Insiders (%) | 4.63% |
| Owned by Institutions (%) | 78.76% |
| Float | 135.10M |
Valuation Ratios
The trailing PE ratio is 16.66 and the forward PE ratio is 22.79. TG Therapeutics's PEG ratio is 1.13.
| PE Ratio | 16.66 |
| Forward PE | 22.79 |
| PS Ratio | 8.31 |
| Forward PS | 6.54 |
| PB Ratio | 12.65 |
| P/TBV Ratio | 11.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.13 |
Enterprise Valuation
| EV / Earnings | 15.59 |
| EV / Sales | 8.61 |
| EV / EBITDA | 50.49 |
| EV / EBIT | 50.49 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 1.29 |
| Debt / EBITDA | 5.53 |
| Debt / FCF | n/a |
| Interest Coverage | 3.64 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 16.58% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 12.11% |
| Revenue Per Employee | $2.00M |
| Profits Per Employee | $1.11M |
| Employee Count | 399 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -339.89M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.38% in the last 52 weeks. The beta is 1.60, so TG Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.60 |
| 52-Week Price Change | +32.38% |
| 50-Day Moving Average | 50.06 |
| 200-Day Moving Average | 36.74 |
| Relative Strength Index (RSI) | 31.86 |
| Average Volume (20 Days) | 2,163,412 |
Short Selling Information
The latest short interest is 30.69 million, so 21.65% of the outstanding shares have been sold short.
| Short Interest | 30.69M |
| Short Previous Month | 30.17M |
| Short % of Shares Out | 21.65% |
| Short % of Float | 22.71% |
| Short Ratio (days to cover) | 10.83 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of $799.54 million and earned $441.49 million in profits. Earnings per share was $2.77.
| Revenue | 799.54M |
| Gross Profit | 658.60M |
| Operating Income | 136.33M |
| Pretax Income | 101.60M |
| Net Income | 441.49M |
| EBITDA | 136.33M |
| EBIT | 136.33M |
| Earnings Per Share (EPS) | $2.77 |
Balance Sheet
The company has $514.43 million in cash and $753.56 million in debt, with a net cash position of -$239.13 million or -$1.69 per share.
| Cash & Cash Equivalents | 514.43M |
| Total Debt | 753.56M |
| Net Cash | -239.13M |
| Net Cash Per Share | -$1.69 |
| Equity (Book Value) | 583.13M |
| Book Value Per Share | 4.11 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was -$13.95 million and capital expenditures -$240,000, giving a free cash flow of -$14.19 million.
| Operating Cash Flow | -13.95M |
| Capital Expenditures | -240,000 |
| Depreciation & Amortization | 102,000 |
| Net Borrowing | 492.66M |
| Free Cash Flow | -14.19M |
| FCF Per Share | -$0.10 |
Margins
Gross margin is 82.37%, with operating and profit margins of 17.05% and 55.22%.
| Gross Margin | 82.37% |
| Operating Margin | 17.05% |
| Pretax Margin | 12.71% |
| Profit Margin | 55.22% |
| EBITDA Margin | 17.05% |
| EBIT Margin | 17.05% |
| FCF Margin | n/a |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 5.56% |
| Shareholder Yield | 5.56% |
| Earnings Yield | 6.64% |
| FCF Yield | -0.21% |
Analyst Forecast
The average price target for TG Therapeutics is $68.57, which is 49.20% higher than the current price. The consensus rating is "Buy".
| Price Target | $68.57 |
| Price Target Difference | 49.20% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 37.49% |
| EPS Growth Forecast (3Y) | 10.38% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 30, 2012. It was a reverse split with a ratio of 1:56.25.
| Last Split Date | Apr 30, 2012 |
| Split Type | Reverse |
| Split Ratio | 1:56.25 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |